喹硫平与利培酮治疗老年痴呆精神行为症状的临床对照研究

A Clinical Controlled Study of Quetiapine and Risperidone in the Treatment of Mental Behavior Symptoms of Alzheimer’s Disease

目的研究喹硫平与利培酮治疗老年痴呆精神行为症状的临床效果。方法方便择取2018年1月-2019年8月该院130例老年痴呆精神行为症状患者作为研究对象,根据随机数字表的方法,将其划分成对照组与实验组,各65例。对照组运用利培酮进行治疗,实验组运用喹硫平进行治疗,在治疗前、治疗后第2、4、8周运用阿尔茨海默病病理行为评分表、药物副反应量表,比较两组的临床疗效与不良反应。结果实验组与对照组治疗后阿尔茨海默病病理行为评分表均显著下降,差异有统计学意义(t=6.042,P=0.002)。对照组显效57例,有效3例,无效5例,总有效率92.31%,实验组显效62例,有效2例,无效1例,总有效率98.46%,组间差异无统计学意义(χ^2=9.073,P=0.08)。实验组治疗2周、治疗4周、治疗8周的TESS评分是(11.00±3.66)分、(9.96±3.10)分、(7.57±2.85)分,对照组分别为(16.29±4.46)分、(14.76±3.90)分、(11.70±3.20)分,实验组的评分显著低于对照组,差异有统计学意义(t=4.092、5.091、10.372,P<0.05)。结论当老年痴呆精神行为症状患者服用喹硫平后,会产生较少的不良反应,因此,该种治疗方法值得在临床中被广泛推广。

Objective To study the clinical effects of quetiapine and risperidone in the treatment of mental behavior symptoms of Alzheimer’s disease. Methods Gonvenient sefeetion of 130 patients with mental behavior symptoms of Alzheimer’s disease in our hospital from January 2018 to August 2019 were selected as subjects. According to the method of random number table, they were divided into control group and experimental group, 65 cases each. The control group was treated with risperidone. The experimental group was treated with quetiapine. Before treatment, at 2, 4,and 8 weeks after treatment,the pathological behavior scores of Alzheimer’s disease and the drug side reaction scale were used. The clinical efficacy and adverse reactions of the group. Results The pathological behavior scores of Alzheimer’s disease in the experimental group and the control group were significantly decreased,and the difference was statistically significant(t=6.042, P=0.002). The control group was markedly effective in 57 cases, effective in 3 cases,ineffective in 5 cases, the total effective rate was 92.31%,the experimental group was markedly effective in 62 cases, effective in 2 cases, and ineffective in 1 case. The total effective rate was 98.46%. The difference between the groups was not statistically significant(χ^2=9.073, P=0.08). The TESS scores of the experimental group for 2 weeks, 4 weeks of treatment, and 8 weeks of treatment were(11.00±3.66)points,(9.96±3.10) points, and(7.57±2.85) points, and the control group was(16.29±4.46) points,(14.76±3.90) points,(11.70±3.20) points, the score of the experimental group was significantly lower than the control group, the difference was statistically significant(t=4.092,3.091,10.372, P<0.05). Conclusion When patients with Alzheimer’s mental behavior symptoms take quetiapine,it will produce fewer adverse reactions. Therefore,this treatment method is worthy of widespread promotion in the clinic.